Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good learning experience for you, newguy.
That's the way the market teaches us, at our expense.
OT. Terry H. and I have both posted here and the Advaxis MB. We have mutually lamented management inadequacies (polite speech here) and held on to shares in LWLG and ADXS due to science with great promise through protracted research and development stages.
Recently ADXS has announced collaborations with AstraZeneca and Merck, so big pharma are starting clinical trials for some of the cancer immunotherapy candidates in the ADXS stable. That's significant validation, and the market is recognizing it. The price target is $13.50 and there are major conference presentations on tap.
ADXS is a disruptive biotech microcap with outstanding clinical and preclinical pipelines where management has rewarded themselves disproportionately so far. I am a LT shareholder and am in the red currently. IMO worth some time for serious DD and a place on your watch list of speculative stocks.
Since the shares of the public company would be delisted, your rational choice, financially speaking, is to accept the offer that is made to shareholders in the financial transaction.
Often there will be an investment bank involved giving a professional assessment of the fairness of the offer.
IMO this is not an immediate concern, but on my radar due to DD. If interested, search with terms "taking public companies private."
The collaboration of Intellicell and Inventiv has great prospects for mutual benefits. You make a reasonable case that a better business model and value proposition are the current focus of Ray Hill. I hope Dr. Victor and the other BOD members work effectively with Ray Hill and Inventiv.
This can be synergistic with Andrews Institute and global agreements as well. Will be interesting to see how this develops.
If SVFC makes significant progress, then it eventually may be taken private. Such an action would cut short the possibility of a valuable legacy stock in my portfolio. It is certainly not an immediate concern to me, but I took note of Ray Hill's past actions as part of my DD. When you have a formula that is successful, you tend to keep using it. Common sense based on public info, that's all.
DoughTrain, I am amazed at the returns you anticipate for SVFC stock.
Right now you can get five shares for a penny. So at 40 cents per share the return would be 200 times, or 20,000 per cent. Wow!
I don't know much about private equity, but would guess deep pockets would not wait until our company reaches a billion dollar MC before taking it private for a much lower, but still lucrative, multiple.
IMO it's more likely that there will be substantial changes in share structure as big money comes in to reap a high multiple with relatively low risk with the public company. If we are still aboard the ship, we are going to have quite a ride. OTOH if SVFC doesn't execute effectively, it could fail to reach its potential in this hot sector. Recent BOD actions and staff additions are encouraging.
It's not so much being right or wrong, but raising awareness of the options. I agree with you and hope some deep pockets investors relieve the pressure on the PPS caused by the toxic loans.
Your point about the relative advantage of share buy back in the $.005 to $.01 range is well taken IMO. I hope whatever happens benefits both current and future shareholders of the company and enables rapid RegenMed progress on a firmer financial footing.
Mave_rick, what the company announced and did was take on the BOD an executive whose last two major accomplishments were building up companies and taking them private. That's significant public information, IMO.
Given those facts, why would the issue of going private be MOOT at this point? I'm quite curious about Ray Hill's skill set and what it may mean for SVFC's current shareholders.
I am eager to see what SVFC says and does. Too much is at stake for many lives for regenerative medicine to fizzle and fail.
I am not focused here on price, gonia.
I'm not much good at guessing what is still future, and especially prices. My portfolio of micro-cap stocks, largely in the red, is proof enough. Still hope that will change for the better with SVFC and other ventures.
My concerns are mainly SVFC goals and timelines.
The addition of Mr. Hill means to me that a strategic decision will be reached by the BOD about continuing as a public shareholding company or taking the company private. He has the particular experience and skill set to inform that decision. IMO that will not take years, but rather months. Look at Hill's history with large firms.
How long current shareholders have to benefit from the technology this company seeks to develop may suddenly change. If it becomes evident that billions are at stake, Hill's efforts may attract deep pocket investors rather quickly. Removing the current risks of toxic financing is vital to this firm moving forward, whether the decision is to keep the company public or take it private.
I'm thinking out loud about what I see is possible due to the addition of Mr. Hill to the BOD. I have no inside information about why him at this time. But the BOD made the decision, and he agreed, for good reasons.
I'm concerned because I would prefer a LT investment in SVFC to become very profitable for me. But I've seen a number of biotechs that had a MC well above the one at the time of the buyout or partnership. Remember the old saying: "Don't count your chickens . . . ."
Very informative link, SitFly. What do you think about the fact that at PPD and IMS the end result of Raymond Hill's leadership was taking the companies private? Whatever he does, he does fairly quickly. Given the results, he must have an impressive bunch of contacts.
"Prior to joining inVentiv Health in 2012, Mr. Hill was CEO at Pharmaceutical Product Development, Inc., where he successfully oversaw the process of taking the company private. Before that, he was President at IMS Consulting Group, where he led an aggressive strategy of organic growth and acquisitions – building the business to $500M in 2010, and then helping to take the company private. Prior to IMS, Mr. Hill held a series of other positions in pharmaceutical consulting."
Mave_rick, an impressive list of expectations. Do you have a link that confirms the Andrews Institute center is being built and near completion?
BTW interesting that you and I bought a lot of our current holdings before what you now call "Possibly and Potentially The BEST TIME Beginning of the Beginning to Buy SVFC For INVESTORS." Hard to pick the lowest price to buy IMO. A reminder that we are speculators in a company with many still unknown facts and many conjectures and hopes.
I certainly hope the toxic debt can be eliminated, but OTOH it's largely responsible for the extremely low PPS that gives us this wonderful buying opportunity -- LOL!
James, your line of reasoning helps me hold on. Tough to do when a publicly traded company operates like a cryptocracy. But that's the pinks.
Undergirding this all is the compelling science. Intellect is not the only company I hold where a few seem to be taking advantage of research intended to benefit many distressed people. It'd time for this venture to turn around and turn out right, IMO.
As good a conjecture as any so far.
The right people will need substantial and well-placed investment funds. That would be a welcome change.
Inveterate, good call from your sense of markets.
Among other things I would guess you recalled past movements and market realities (insiders always get the jump on the public investors).
Another example of volume preceding price in a significant move. Maybe LT investors will get out of this ditch eventually.
I can't attend the ASM. Would someone please ask if Dr. Anthony Arduengo, University of Alabama chemistry professor, is still managing the patent application listed on his personal web page.
"U.S. Patent Appl. 2011/062627
Filed Nov. 31, 2011, - Stable free radical Chromophores and Mixtures thereof, Processes for Preparing the same, Nonlinear Optical Materials, and Uses thereof in Nonlinear Optical Applications (with F. J. Goetz, Sr., A. Ashton, F. J. Goetz, Jr., D. F. Eaton, H. E. Simmons, III, and J. W. Runyon)."
Might securing this patent reinvigorate the cooperative efforts of Dr. Arduengo and LWLG to develop photovoltaic products?
Is the granting of this patent important for other product developments by LWLG?
Not sure if this is best handled in public Q&A time or after the formal meeting. Dr. Eaton may be the best contact. Reference my post #12315.
TIA.
Info
Got slightly over that amount yesterday at the ask in one transaction. Early this morning the spread was temporarily lower, But after the news today, the ask at 13 went to very small size. All a matter of timing and MM response to supply/demand.
Let's understand that the funding details will be vital for future growth higher share price, and attracting more investors.
Also wary onlookers will need more than the current announcement. IMO it will stem the PPS drop but may not persuade many to risk initial share purchases or to increase their current commitments. They will need more reports of similar commitments and progress.
Why? Because too many financial resources went in the wrong direction. Because past announcements of international agreements had no accountability and resulted in no licensing fees. Because recent toxic financing continues to roil the MB. Because huge authorized share increases may lead to greater dilution, etc. The proof will be in maintaining current and future agreements with responsible and reputable regenerative medical professionals. Substantial revenues will certainly build credibility.
The current list of numerous collaborators is impressive and encouraging. The new hires have the credentials and experience to build substantial revenues. We just got the sizzle in the air; getting the steak on our plates will take a while!
Enthusiastically agree!
Intellicell is not going to be 'just another pink." No way! These new staff show SVFC intends to provide great complements to our top-level alliances. Experience and contacts count -- it's no time for rookies on the RegenMed team.
More quality staff is an investment that will pay off big time, IMO. I've added more shares this week.
Well said. Long also and agree on this topic. Routine required reports are not a surprise to anyone.
I very much look forward to the financial side of the Co. matching the innovative brilliance of the biotech/medical side. This will be more critical as alliances with eminent collaborators move to deliver groundbreaking services on larger scales in more locations.
Investors expect competent financial operations (timeliness being only one aspect of the whole package) when so much is at stake in the big picture. I expect those shareholders who see so much promise, as I do, also support management and BOD decisions that will enable the staff to achieve their goals.
Newsflash -- Two new staff added today: Director of National Sales and interim CFO.
What is the current assessment of ESPH? TIA.
Hi Terry,
Intriguing story. My Profs in Ag and Natural Sciences at PSU served me better than the one you saw in Nam. I was an undergrad as Nam heated up. Some of my classmates served there, and they survived like you did.
I cannot fathom the complexities of the science of biotechnology or photonics, so do the best I can with publicly disclosed stuff. As a PT self-employed retail investor I explore for available sources on spec stocks and follow MBs.
The number of microcap stocks with managements that have enriched themselves at shareholders expense is dismaying -- I've run afoul of more than I care to recount. Too many stories of potential riches for the many and actual payouts to a few. IMO it's too soon to tell about the managements we're discussing here.
What are the odds that both ADXS and LWLG will become blockbusters in the future? Certain actions / bumblings bother me, but the potential for both is what keeps me hanging on. I could be devoured by lions -- and not those in the Nittany den. LOL!
Best,
Info
Maybe IBM's graphene will face unexpected competition.
Could hemp nanosheets topple graphene for making the ideal supercapacitor?
Quote:
As hemp makes a comeback in the U.S. after a decades-long ban on its cultivation, scientists are reporting that fibers from the plant can pack as much energy and power as graphene, long-touted as the model material for supercapacitors. They're presenting their research, which a Canadian start-up company is working on scaling up, at the 248th National Meeting & Exposition of the American Chemical Society (ACS).
David Mitlin, Ph.D., explains that supercapacitors are energy storage devices that have huge potential to transform the way future electronics are powered. Unlike today's rechargeable batteries, which sip up energy over several hours, supercapacitors can charge and discharge within seconds. But they normally can't store nearly as much energy as batteries, an important property known as energy density. One approach researchers are taking to boost supercapacitors' energy density is to design better electrodes. Mitlin's team has figured out how to make them from certain hemp fibers—and they can hold as much energy as the current top contender: graphene.
"Our device's electrochemical performance is on par with or better than graphene-based devices," Mitlin says. "The key advantage is that our electrodes are made from biowaste using a simple process, and therefore, are much cheaper than graphene."
The race toward the ideal supercapacitor has largely focused on graphene—a strong, light material made of atom-thick layers of carbon, which when stacked, can be made into electrodes. Scientists are investigating how they can take advantage of graphene's unique properties to build better solar cells, water filtration systems, touch-screen technology, as well as batteries and supercapacitors. The problem is it's expensive.
Mitlin's group decided to see if they could make graphene-like carbons from hemp bast fibers. The fibers come from the inner bark of the plant and often are discarded from Canada's fast-growing industries that use hemp for clothing, construction materials and other products. The U.S. could soon become another supplier of bast. It now allows limited cultivation of hemp, which unlike its close cousin, does not induce highs.
Scientists had long suspected there was more value to the hemp bast—it was just a matter of finding the right way to process the material.
"We've pretty much figured out the secret sauce of it," says Mitlin, who's now with Clarkson University in New York. "The trick is to really understand the structure of a starter material and to tune how it's processed to give you what would rightfully be called amazing properties."
His team found that if they heated the fibers for 24 hours at a little over 350 degrees Fahrenheit, and then blasted the resulting material with more intense heat, it would exfoliate into carbon nanosheets.
Mitlin's team built their supercapacitors using the hemp-derived carbons as electrodes and an ionic liquid as the electrolyte. Fully assembled, the devices performed far better than commercial supercapacitors in both energy density and the range of temperatures over which they can work. The hemp-based devices yielded energy densities as high as 12 Watt-hours per kilogram, two to three times higher than commercial counterparts. They also operate over an impressive temperature range, from freezing to more than 200 degrees Fahrenheit.
http://phys.org/news/2014-08-hemp-nanosheets-topple-graphene-ideal.html
ijeffc, as a graduate of Penn State I doubt that the university knows much about Advaxis. The release about the company's restructured exclusive license agreement was with the University of Pennsylvania in Philadelphia. This prestigious Ivy League school commonly refers to itself as Penn or UPenn. Dr. Yvonne Peterson, the company's founder, is an acclaimed professor at UPenn. The Penn Center for Innovation has given Advaxis a significant vote of confidence with this new agreement. I hope they along other stakeholders are nicely rewarded.
OTOH the Keystone state's Land Grant institution alumni let others know that "We are Penn State." One of our distinguished alumni is Dr. Joe Miller, a BOD member of Lightwave Logic (LWLG). For years this development stage company has been on the cusp of commercializing its organic polymers in a number of phototonic devices. Rear Admiral (Ret.) Tom Zelibor, the CEO says "We intend to show the world an array of working devices in not one, but in a multitude of applications and industries." As a high tech speculative stock it has similarities to Advaxis -- most notably the possibility of big impact in several major markets. It differs from ADXS in having leadership that is more accomplished in past endeavors and more aligned with the interests of shareholders, IMO. Of course it has major competition, but no FDA approvals needed and no debt. Worth a look; do your DD. I intend this to be informative, not a pump.
When clinics are set up in license agreements with hospitals then the clinics must operate under the same standards as the hospitals according to the Joint Commission. The JC would review and approve the clinics along with the hospitals as regular procedure. Would this not give a lot of cred to the approved clinics compared with standalone competition?
Since the FDA has an approval process for INDs, I assume hospitals and their associated clinics would adhere to the FDA decisions in that area. Is my assumption correct?
It's always good to have more than one arrow in the disruptive tech quiver. You've been a strong advocate for resource juniors as well. I've done well in WLDCF, which like NIOBF is now pulling back after a good gain.
I continue to be overweighted in LWLG, but also added UNXL today after a disappointing report and big share sale. Like LWLG, it's an overdue disruptive tech venture working with Kodak on innovative touch screens. Now it's time to wait and see what the market brings.
Been watching UNXL for commercial production with Kodak. Hope it happens this yr., or soon thereafter.
Dump-out this AM meant good entry point for me after getting funds from other gains. Best to all longs.
Perhaps an unintended consequence of success at / for U. of Delaware:
"The Hu group will be moved to MIT Department of Materials Science & Engineering officially starting 2015."
Since SVFC filed with the FDA for a clinical trial for osteoarthritis at InVentiv, should we assume that they are funding the trial? Again, more immediate expenses for LT potential.
Immediate response in market: volume holding at 60 million shares, Bid .0020. Ask .0022, Last .0021 -- No Change. Note that when Dr. Andrews is involved, the research goes for FDA approval. No shortcuts in expense or time, but IMO positions them at the top of a very competitive field in the long run.
Dediu's fascinating graphics could gain additional analytical value by adding the U.S. and world population (or consumer units) lines. He overlaid a personalized perspective, which I appreciated. Stimulating stuff! Thanks, Steve.
Strange -- soon after you and another posted buys at 19 cents the market dropped to 17/18. MMs are tough cookies.
Maybe, but more likely because my portfolio is full of spec stocks that have been hyped by all-in pumpers like mave without sustained pps gains. The market is littered with them, and I have my share.
Besides, I tend to be an on balance investor -- weighing pros and cons as best I can. Some MB posters help me with evaluating stocks more than others. I consider bold type bashers and pumpers alike an annoyance. But this is an open forum. I don't intend to censure anyone, rather encourage them to share accurate information. I can quickly skip over posts that don't help me, and you should feel free to ignore mine. I hope your enthusiasm is well-founded.
BTW, I am the one who posted the USA Today Sports article on July 29th about Dr. Andrews and NFL players, #73771. Maybe that helps, Info.
Handy, wish I had read your post before I replied to mave.
My error. Mostly I'm a lurker and occasional poster, but not an Ihub subscriber.
Please take a deep breath, mave.
Maybe just an unfortunate typo, but where did you get that $30 million? Over 30 million shares were traded, but at $0.0018 per share the total trades for the day amounted to about $55K. FWIW, the market cap of SVFC is about $2.40 million, a figure nicely supplied by IHUB in the detailed quote.
To compare with another AM penny stock, TECL traded over 76 million shares today at an average price of $0.0016. So total amount traded was a bit over $122K. Current market cap is $827K.
For sure these speculative sub-penny stocks are not the focus of big market movers. But it's nice to think we are getting in on the ground floor of medical stocks with vast healthcare potential through innovative technology processes. Let others do their DD and decide if they want to join us.
The linking of NFL stars with Dr. Andrews and Dr. Victor pumps us up due to our self interest. We'll see how much the market pays attention. It's certainly nice to be up when the market is down big; my best mover this week is LWLG.
Thanks to all of you for highlighting critical issues in the shareholders letter and 8-K filing. There was so much material I didn't have time or knowledge to digest many details or understand the significance of key points.
Most important to me the agreements reached enable ILNS to continue as an operating company with a chance to develop its IP. Seems like this stock may become a more valuable part of my portfolio.
More than one point of view is represented, of course. That's what makes markets so interesting and problematic. The future prospects for ILNS are improving, IMO.
Dubai shows the great potential in international markets. IMO at the present time the best equipped company to treat serious injuries in Middle East racing is Therapy Cells, Inc. and not Intellicell Biosciences. Why?
Most importantly TCI has an effective procedure developed by Australian veterinarian Dr. Patrick J. Casey, a clinician and researcher. The active Ihub site for TCEL highlights the story of a severely injured show jumping horse saved by the patented procedure for growing adult cells (see the sticky). The Co. web site tells of a trotter restored to winning form. Dislosure: I hold shares in both companies.
Also long and believe another reason for caution are the references to the FDA in the SI article.
"Andrews and his team of doctors have been limited in what they can offer by a strict adherence to guidelines from the Food and Drug Administration. So far, that’s meant sticking to one procedure: Harvesting cells from a player’s bone marrow and putting them back into his or her body, unaltered, at the site of injury."
Assuming this is accurate reporting, IMO it means Dr. Andrews is not going to jeopardize his current success and future prospects by doing anything that goes beyond FDA guidelines. He definitely wants to occupy the ethical high ground.
His team is building procedural excellence in the biologics arena. So they are laying the basis for further FDA approvals based on scientifically based research and subsequent clinical practice. It seems to me that Dr. Victor is going on a parallel track with SVFC. Does this mean they will collaborate on research?
Biologics research at a customized facility will require money, time, and talent in order to pass regulatory scrutiny. Do it right, and the results will be worth it. If SVFC is a partner in this advance, surely more investors will find it attractive.
Dr. James Andrews continues to help injured NFL players.
"Denver Broncos cornerback Chris Harris passed his six-month post-anterior cruciate ligament reconstruction check-up with famed orthopedist James Andrews and could return to practice soon, a person informed of Harris' status told USA TODAY Sports.
The person spoke on condition of anonymity because the Broncos haven't announced an update on Harris' status.
Harris suffered a torn ACL in the divisional-round playoff win against the San Diego Chargers in January and had surgery a week after the Super Bowl defeat to the Seattle Seahawks the following month.
He was the only Denver player to open training camp on the physically unable to perform list. Getting clearance from Andrews is a big step toward returning to the active roster and participating in practice.
It will now be up to the Broncos now when Harris will be cleared to practice. When he does receive the green light, expect the team to bring him along slowly.
By comparison, outside linebacker Von Miller, who had ACL surgery about a month before Harris, was allowed to participate in individual drills during a minicamp in June and is participating in practices now. Still, Miller is being held out of full-contact drills.
Miller had a similar checkup with Andrews a month ago and talked to Harris about it Sunday night.
'What I did on a test he should be able to do that and more, because he's been doing the same stuff that I've been doing. I'm excited to hear back and hear Dr. Andrews' feedback and I know it will all be positive because he's been grinding,' Miller told reporters after practice Monday."
http://www.usatoday.com/story/sports/nfl/broncos/2014/07/28/chris-harris-acl-denver-cornerback/13280851/
KCCO, thanks for the list with especially helpful selected quotes and summary statements.
Dynamite opening paragraphs. Your history with Lightwave, current intentions, hopes, and cautions provided context and credibility right up front.
A curious computer glitch/gremlin: How did "Lightwave Logic Retains Stonegate Securities ..." become "Lightwave Logic Retails Stonegate Securities ..."? LOL
I really don't know much about those insiders. About three months ago I bought some shares at .02 and thought they were a steal. What did I know? Since then I've seen many posts about past intrigues and guessed that there are more mysteries in OPXS than I imagined. But am still holding for LT. Also I'm glad I got more ILNS than OPXS even though the MB drama is more intense.
Well, not exactly. Most of my holdings have been range bound or slowly drifting toward new lows like SVFC. Rather boring. But ...
some biotechs like SNSS have risen nicely in the past week, and ...
regen medicine penny TCEL has exploded in this week, trading multiples of the 369 million float in the past four days.
Have any of you noticed TCEL? Some inspiring stories about removing, growing, and transplanting tendon cells in race horses on the web site. On the stock scene, lots of P&D noisemakers and an enigmatic announcement by management yesterday (on the Co. web site, not a PR release). Disclosure: I took a small position with little financial consequences at this time. The LT may be good -- who knows?
BTW, why do these wonderful regen med docs seem to do flakey things on the business side? I know they have to raise funds, that's a given. But if the medical techniques are so carefully done for the benefit of the patients, why don't their financial backers get the same consideration?